(PDF) P1.01-78 the Incidence of Brain Metastases in

P1.01-78 the Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.634

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-113 Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

Crizotinib in MET Deregulated or ROS1 Rearranged Pretreated Non-Small-Cell Lung Cancer (METROS): A Phase II, Prospective, Multicentre, Two-Arms Trial

Clinical Cancer Research

Cancer Research

English

P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated With High Rate of Venous Thromboembolism: Analysis of the METROS Trial

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea

Journal of Thoracic Oncology

Respiratory Medicine

English

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.13-07 the Effect of Crizotinib in Patients of Non Small Cell Lung Cancer With Brain Metastases: A Retrospective Analysis

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

Oncology Letters

Cancer Research

English